BeiGene Collaboration

3 Months Ended

Sep. 30, 2019

Note 4. BeiGene Collaboration

In October 2018, we entered into a clinical collaboration with BeiGene, Ltd. (“BeiGene”) to evaluate the safety and efficacy of

ME-401

in combination with BeiGene’s zanubrutinib, an investigational inhibitor of Bruton’s tyrosine kinase (“BTK”), for the treatment of patients with

B-cell

malignancies. Under the terms of the clinical collaboration agreement, we amended our ongoing Phase 1b trial to include evaluation of

ME-401

in combination with zanubrutinib in patients with

B-cell

malignancies. Study costs are being shared equally by the parties, and we agreed to supply

ME-401

and BeiGene agreed to supply zanubrutinib. We record the costs reimbursed by BeiGene as a reduction of our research and development expenses. We retained full commercial rights for

ME-401

and BeiGene retained full commercial rights for zanubrutinib.